LEADER 02030nam  2200457   450 
001 9910715327503321
005 20210304110643.0
035   $a(CKB)5470000002510762
035   $a(OCoLC)1240422157
035   $a(EXLCZ)995470000002510762
100   $a20210304d2021      ua             0
101 0 $aeng
135   $aur|||||||||||
181   $ctxt$2rdacontent
182   $cc$2rdamedia
183   $acr$2rdacarrier
200 10$aDrug safety: FDA's future inspection plans need to address issues presented by COVID-19 backlog $etestimony before the Subcommittee on Agriculture, Rural Development, Food and Drug Administration, and Related Agencies, Committee on Appropriations, House of Representatives /$fstatement of Mary Denigan-Macauley
210  1$a[Washington, D.C.] :$cUnited States Government Accountability Office,$d2021.
215   $a1 online resource (18 pages) $ccolor illustrations, color map
225 1 $aTestimony ;$vGAO-21-409T
300   $a"For release on delivery, expected at 10:00 a.m. ET, Thursday, March 4, 2021."
320   $aIncludes bibliographical references.
517   $aDrug safety
606   $aCOVID-19 (Disease)$xTreatment$zUnited States
606   $aCOVID-19 Pandemic, 2020-$zUnited States
606   $aDrugs$xInspection$zUnited States
606   $aDrugs$zUnited States$xSafety measures
606   $aDrug reimportation$zUnited States
615  0$aCOVID-19 (Disease)$xTreatment
615  0$aCOVID-19 Pandemic, 2020-
615  0$aDrugs$xInspection
615  0$aDrugs$xSafety measures.
615  0$aDrug reimportation
702   $aDenigan-Macauley$b Mary
712 02$aUnited States.$bCongress.$bHouse.$bCommittee on Appropriations.$bSubcommittee on Agriculture, Rural Development, Food and Drug Administration, and Related Agencies,
801  0$bGPO
801  1$bGPO
906   $aBOOK
912   $a9910715327503321
996   $aDrug safety: FDA's future inspection plans need to address issues presented by COVID-19 backlog$93523347
997   $aUNINA